L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lytix Biopharma AS
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Other Non-Cash Items
kr4.2m
CAGR 3-Years
-21%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Other Non-Cash Items
-kr15.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bergenbio ASA
OSE:BGBIO
Other Non-Cash Items
-kr254k
CAGR 3-Years
N/A
CAGR 5-Years
43%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Other Non-Cash Items
-kr2.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
N
Nykode Therapeutics ASA
OSE:NYKD
Other Non-Cash Items
-$11m
CAGR 3-Years
N/A
CAGR 5-Years
-114%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Other Non-Cash Items
-kr28.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

What is Lytix Biopharma AS's Other Non-Cash Items?
Other Non-Cash Items
4.2m NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Other Non-Cash Items amounts to 4.2m NOK.

What is Lytix Biopharma AS's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 5Y
4%

Over the last year, the Other Non-Cash Items growth was 204%. The average annual Other Non-Cash Items growth rates for Lytix Biopharma AS have been -21% over the past three years , 4% over the past five years .

Back to Top